JP2023175830A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023175830A5 JP2023175830A5 JP2023150164A JP2023150164A JP2023175830A5 JP 2023175830 A5 JP2023175830 A5 JP 2023175830A5 JP 2023150164 A JP2023150164 A JP 2023150164A JP 2023150164 A JP2023150164 A JP 2023150164A JP 2023175830 A5 JP2023175830 A5 JP 2023175830A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- antigen
- binding fragment
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862682042P | 2018-06-07 | 2018-06-07 | |
| US62/682,042 | 2018-06-07 | ||
| KR10-2019-0066622 | 2019-06-05 | ||
| JP2020567832A JP7390317B2 (ja) | 2018-06-07 | 2019-06-05 | 抗Ｔｉｅ２抗体およびその使用 |
| PCT/KR2019/006820 WO2019235856A1 (ko) | 2018-06-07 | 2019-06-05 | Tie2에 결합하는 항체 및 이의 용도 |
| KR1020190066622A KR102898574B1 (ko) | 2018-06-07 | 2019-06-05 | Tie2에 결합하는 항체 및 이의 용도 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567832A Division JP7390317B2 (ja) | 2018-06-07 | 2019-06-05 | 抗Ｔｉｅ２抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023175830A JP2023175830A (ja) | 2023-12-12 |
| JP2023175830A5 true JP2023175830A5 (https=) | 2024-03-18 |
| JP7700189B2 JP7700189B2 (ja) | 2025-06-30 |
Family
ID=69056780
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567832A Active JP7390317B2 (ja) | 2018-06-07 | 2019-06-05 | 抗Ｔｉｅ２抗体およびその使用 |
| JP2023150164A Active JP7700189B2 (ja) | 2018-06-07 | 2023-09-15 | 抗Ｔｉｅ２抗体およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567832A Active JP7390317B2 (ja) | 2018-06-07 | 2019-06-05 | 抗Ｔｉｅ２抗体およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12024562B2 (https=) |
| EP (2) | EP3805265A4 (https=) |
| JP (2) | JP7390317B2 (https=) |
| KR (1) | KR102898574B1 (https=) |
| CN (1) | CN112399975B (https=) |
| AU (2) | AU2019283520A1 (https=) |
| CA (1) | CA3101506A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7447144B2 (ja) * | 2019-08-14 | 2024-03-11 | ファームアブシン・インコーポレイテッド | 抗ｔｉｅ２抗体及びその用途 |
| AU2021242249A1 (en) * | 2020-03-24 | 2022-08-18 | Genentech, Inc. | Tie2-binding agents and methods of use |
| KR102899889B1 (ko) * | 2020-11-03 | 2025-12-18 | 한국생명공학연구원 | 신규 항-Tie2 항체 또는 이의 항원 결합 단편, 및 이의 용도 |
| WO2022235090A1 (ko) * | 2021-05-06 | 2022-11-10 | 기초과학연구원 | Tie2 작용제 항체 및 이의 용도 |
| KR20250005053A (ko) * | 2022-01-13 | 2025-01-09 | 인제니아 테라퓨틱스 인크. | Vegf 및 tie2-결합 융합 단백질 및 그의 용도 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPM379494A0 (en) * | 1994-02-10 | 1994-03-03 | Ludwig Institute For Cancer Research | Immunointeractive molecules - ii |
| AU689232B2 (en) * | 1994-02-10 | 1998-03-26 | Ludwig Institute For Cancer Research | An immunointeractive molecule which binds the (TIE)2/TEK receptor extracellular domain |
| JP2000041675A (ja) * | 1998-07-31 | 2000-02-15 | Nichirei Corp | ヒトｔｅｋに対する抗体 |
| US6365154B1 (en) * | 1998-09-28 | 2002-04-02 | Smithkline Beecham Corporation | Tie2 agonist antibodies |
| US6376653B1 (en) * | 1998-09-28 | 2002-04-23 | Smithkline Beecham Plc | Tie2 antagonist antibodies |
| US20090137416A1 (en) * | 2001-01-16 | 2009-05-28 | Regeneron Pharmaceuticals, Inc. | Isolating Cells Expressing Secreted Proteins |
| US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US20040101920A1 (en) * | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| JP2011102273A (ja) | 2009-11-11 | 2011-05-26 | Shiseido Co Ltd | Ｔｉｅ２活性化剤、血管の成熟化、正常化又は安定化剤、リンパ管安定化剤並びにしわ防止・改善剤及びむくみ改善・予防剤 |
| US10316105B2 (en) | 2011-08-19 | 2019-06-11 | Regeneron Pharmaceuticals, Inc. | Anti-TIE2 antibodies and uses thereof |
| MX359833B (es) * | 2011-08-19 | 2018-10-12 | Regeneron Pharma | Anticuerpos anti-tie2 y usos de los mismos. |
| KR102196450B1 (ko) | 2013-09-17 | 2020-12-30 | 삼성전자주식회사 | Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제 |
| JP6346761B2 (ja) | 2014-03-07 | 2018-06-20 | 丸善製薬株式会社 | Ｔｉｅ２活性化剤、並びに医薬品組成物、及び経口組成物 |
| JP6699551B2 (ja) * | 2014-07-15 | 2020-05-27 | アステラス製薬株式会社 | 新規抗ヒトＴｉｅ２抗体 |
| CN106994185B (zh) * | 2016-01-22 | 2021-04-06 | 何玉龙 | Tie2对视网膜及其他组织中静脉血管的保护作用及应用 |
| JP2018043949A (ja) | 2016-09-15 | 2018-03-22 | サンスター株式会社 | Ｔｉｅ２活性用組成物 |
-
2019
- 2019-06-05 EP EP19814472.7A patent/EP3805265A4/en active Pending
- 2019-06-05 KR KR1020190066622A patent/KR102898574B1/ko active Active
- 2019-06-05 AU AU2019283520A patent/AU2019283520A1/en not_active Abandoned
- 2019-06-05 JP JP2020567832A patent/JP7390317B2/ja active Active
- 2019-06-05 CA CA3101506A patent/CA3101506A1/en active Pending
- 2019-06-05 CN CN201980038199.8A patent/CN112399975B/zh active Active
- 2019-06-05 EP EP25173861.3A patent/EP4591878A3/en active Pending
-
2020
- 2020-12-03 US US17/111,413 patent/US12024562B2/en active Active
-
2023
- 2023-09-15 JP JP2023150164A patent/JP7700189B2/ja active Active
-
2024
- 2024-05-17 US US18/667,700 patent/US20250011438A1/en active Pending
-
2026
- 2026-03-18 AU AU2026202090A patent/AU2026202090A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023175830A5 (https=) | ||
| JP5795759B2 (ja) | 抗ＴＮＦ−α抗体およびその用途 | |
| US20230242651A1 (en) | Stable antibody variable domain framework combinations | |
| CN103384682B (zh) | 结合il‑17a和il‑17f的抗体分子 | |
| JP2021526801A5 (https=) | ||
| JP6802381B2 (ja) | Ｉｌ−１７ａに特異的に結合する可能な抗体及びその機能的断片 | |
| US10400037B2 (en) | Binding molecules, especially antibodies, binding to L1CAM (CD171) | |
| CA3201064A1 (en) | Anti-human b7-h3 antibody and application thereof | |
| WO2022135536A1 (zh) | Cd3人源化抗体及其应用 | |
| RS55031B1 (sr) | Molekuli antitela koji vezuju interleukine il-17a i il-17f | |
| US20250051467A1 (en) | Fap/cd40 binding molecule and medicinal use thereof | |
| JP2026041845A5 (https=) | ||
| CA3007493A1 (en) | Multi-specific antibody molecules having specificity for tnf-alpha, il-17a and il-17f | |
| JP2022115961A (ja) | 親和性を操作した血清タンパク質担体結合ドメイン | |
| JP4642862B2 (ja) | ヒト腫瘍壊死因子−アルファに特異的なヒト化抗体 | |
| JP2023547662A5 (https=) | ||
| CN114829394A (zh) | 多特异性抗体 | |
| CN107118273B (zh) | 一种全人源抗补体因子h的抗体 | |
| CN117024587A (zh) | 人IL-1β蛋白结合分子及其编码基因和应用 | |
| US10947305B2 (en) | Anti-TNFα binding compounds and uses thereof | |
| EP4448574A1 (en) | Polypeptides comprising immunoglobulin single variable domains targeting tcralphabeta, cd33 and cd123 | |
| TW202528354A (zh) | B7-h3結合蛋白及其用途 | |
| WO2026056853A1 (zh) | Tl1a抗体及其应用 | |
| WO2025140010A1 (zh) | 抗cd3抗体及其用途 | |
| CN119451698A (zh) | 抗il-25抗体及其使用方法 |